Press release
Interim Report July – September 2018
Summary of Q3
Financial overview July 1 – September 30 2018
- Net sales amounted to SEK 0.0 M (0.0)
- Loss for the period was SEK 103.0 M (loss: 51.6)
- Loss per share, before and after dilution, was 2.34 (loss: 1.30) SEK
- On September 30 cash and cash equivalents amounted to SEK 488.9 M (443.0)
Significant events during the period July 1 to September 30 2018
- During September, the first patient-initiated treatment in Oncopeptides’ Phase II-study BRIDGE with Ygalo® in RRMM patients with renal impairment
- Anders Martin-Löf appointed as new Chief Financial Officer and commences his position in November
- Oncopeptides’ first Capital Markets Day to be held in New York on December 14th
Financial overview of the group
| SEK thousand | 2018 Jul-Sep |
2017 Jul-Sep |
2018 Jan-Sep |
2017 Jan-Sep |
2017 Jan-Dec |
| Net sales | – | – | – | – | – |
| Operating loss | -102,982 | -51,573 | -308,088 | -180,916 | -247,620 |
| Loss before tax | -102,982 | -51,573 | -308,088 | -180,916 | -247,620 |
| Loss for the period | -102,982 | -51,573 | -308,088 | -180,916 | -247,620 |
| Earnings per share before and after dilution (SEK) | -2.34 | -1.30 | -7.24 | -4.78 | -6.44 |
| Cash flow from operating activities | -93,506 | -86,158 | -224,872 | -225,818 | -271,497 |
| Cash and cash equivalents at the end of the period |
488,869 | 442,964 | 488,869 | 442,964 | 404,050 |
| Research & development costs/ operating expenses % | 75% | 94% | 75% | 80% | 80% |
| Financial calendar | |
| Year-end report 2018: | February 22, 2019 |
| Interim report Q1: | May 21, 2019 |
| Interim report Q2: | July 12, 2019 |
| Interim report Q3: | November 19, 2019 |
For further information, please contact:
Jakob Lindberg, CEO, Oncopeptides
E-mail: jakob.lindberg@oncopeptides.se
Telephone: +46 (0)8 615 20 40
Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: rein.piir@oncopeptides.se
Cell phone: +46 (0)70 853 72 92
About Oncopeptides
Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate Ygalo®, an alkylating peptide, belonging to a new class of drugs (Peptidase Enhanced Compounds – PEnCs). Ygalo® is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with Ygalo® compared with established alternative drugs for patients with late-stage multiple myeloma. Ygalo® will potentially provide physicians with a new treatment option for patients suffering from this serious disease.
The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on October 26, 2018, at 08.00 (CET).
Visit www.oncopeptides.se for more information.